Spots Global Cancer Trial Database for golimumab
Every month we try and update this database with for golimumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D | NCT04729296 | Diabetes Mellit... | Golimumab Placebo | 3 Years - 46 Years | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy | NCT00361335 | Rheumatoid Arth... | Golimumab Methotrexate Placebo | 18 Years - | Centocor, Inc. | |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | NCT05960578 | Castration-Resi... Prostate Adenoc... | Apalutamide Biopsy Biospecimen Col... Computed Tomogr... Golimumab Magnetic Resona... PSMA PET Scan | 18 Years - | University of Washington | |
| Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D | NCT04729296 | Diabetes Mellit... | Golimumab Placebo | 3 Years - 46 Years | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | |
| Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab | NCT02186886 | Ulcerative Coli... | Golimumab | 18 Years - | Kliniken im Naturpark Altmuehltal | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | NCT01804166 | Hepatosplenic T... | Infliximab Golimumab | - | Janssen Scientific Affairs, LLC | |
| Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab | NCT02186886 | Ulcerative Coli... | Golimumab | 18 Years - | Kliniken im Naturpark Altmuehltal | |
| A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy | NCT00361335 | Rheumatoid Arth... | Golimumab Methotrexate Placebo | 18 Years - | Centocor, Inc. | |
| A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | NCT01804166 | Hepatosplenic T... | Infliximab Golimumab | - | Janssen Scientific Affairs, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
